Ocular Drug Delivery System Challenges and New Advancements

Ocular medication delivery remains one of the most difficult areas of pharmaceutical science due to the eye's unique anatomical and physiological obstacles. Drug absorption and bioavailability are considerably limited by protective mechanisms including as tear turnover, blinking, nasolacrimal drainage, corneal epithelial tight junctions, and the blood-aqueous and blood-retinal barriers. Conventional dose formulations, such as eye drops and ointments mostly have a short residence time and low therapeutic efficacy, demanding frequent administration and resulting to lower patient compliance. Furthermore, posterior segment disorders such as age-related macular degeneration, diabetic retinopathy, and glaucoma necessitate focused and continuous drug delivery techniques that overcome both static and dynamic ocular obstacles. Recent advancements in ocular drug delivery systems have focused on improving bioavailability, prolonging precorneal retention, enabling controlled release, and enhancing tissue targeting. Innovative approaches include nanoparticle-based systems (polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers), liposomes, niosomes, dendrimers, micelles, and in situ gelling systems. Biodegradable and non-biodegradable implants, microneedles, ocular inserts, and contact lens mediated delivery have also demonstrated promising outcomes for sustained and site-specific therapy. Furthermore, emerging technologies such as stimuli-responsive systems, gene delivery vectors, and nanofiber-based platforms are expanding therapeutic possibilities for both anterior and posterior segment disorders.